Singapore-based SCG Cell Therapy has signed an agreement to establish an innovation center in Wuxi, marking a milestone in China-Singapore collaboration in advanced biomedicine.

SCG Cell Therapy is a global leader in TCR-T cell therapy. Its flagship pipeline, SCG101, is the world's only therapy designed to simultaneously eliminate the hepatitis B virus and liver cancer cells and has already entered pivotal clinical trials.

The new innovation center will focus on advancing the company's proprietary TCR screening platform and developing natural T-cell receptors (TCRs) with high affinity and strong anti-tumor activity for solid tumor treatment. The project is expected to inject fresh momentum into Wuxi's rapidly growing cell therapy industry.

Wuxi and Singapore share a long-standing partnership. In the 1990s, Singapore established China's first industrial park in Wuxi — the Wuxi-Singapore Industrial Park — laying the foundation for decades of economic cooperation.

Bilateral trade has continued to expand. In 2025, Wuxi's total trade with Singapore reached $4.15 billion, up 12.9 percent year-on-year, with exports rising 20.1 percent to $2.19 billion. As of March 2026, Singapore's cumulative utilized foreign investment in Wuxi had reached $7.2 billion.